Literature DB >> 15075538

Interleukin-2 immunotherapy exerts a differential effect on CD4 and CD8 T cell dynamics.

Giulia Marchetti1, Luca Meroni, Chiara Molteni, Alessandra Bandera, Fabio Franzetti, Massimo Galli, Mauro Moroni, Mario Clerici, Andrea Gori.   

Abstract

BACKGROUND: Emerging evidence indicates that CD4 and CD8 T cell recovery is differentially regulated during HIV infection. The hallmark of interleukin-2 (IL-2)-induced immune reconstitution is the selective outgrowth of CD4 through undefined mechanisms.
OBJECTIVE: To delineate the effect of IL-2 on T cell homeostasis by analysing the differential impact of IL-2 immunotherapy on CD4 and CD8 dynamics.
DESIGN: A randomized trial of 15 HIV-positive patients, eight receiving IL-2 immunotherapy with highly active antiretroviral therapy (HAART) and seven with HAART alone. Patients were followed for a 48-week period following three IL-2 cycles (overall, 10 weeks in duration).
METHODS: CD4 and CD8 count, naive and memory immunophenotype, proliferation by Ki67, and CD8+CD38+ activated pattern were measured longitudinally by flow cytometry. Thymic output contribution to both CD4 and CD8 was evaluated by measurement of T cell receptor excision circles (TREC). Wilcoxon test was used to compare results.
RESULTS: Compared with changes seen with HAART alone, IL-2 induced a more significant rise in CD4 than CD8 T cell count (P < 0.01), associated with a significant increase in Ki67-proliferating CD4 (P < 0.05), whereas no changes were seen in CD8+Ki67+ (P > 0.05). Furthermore, IL-2 administration was associated with CD4 TREC increase, whereas CD8 TREC remained stable (P > 0.05). Modifications in CD4 and CD8 T cells seen in patients taking only HAART were not associated with changes in CD4 and CD8 TREC.
CONCLUSIONS: By showing a differential impact on CD4 and CD8 homeostasis, the study suggests that IL-2-associated immune reconstitution results from protean interactions between T cell compartments; this has significant implications for the correct planning of immunotherapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15075538     DOI: 10.1097/00002030-200401230-00010

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  7 in total

1.  Contribution of T cell subsets to the pathophysiology of Pneumocystis-related immunorestitution disease.

Authors:  Samir P Bhagwat; Francis Gigliotti; Haodong Xu; Terry W Wright
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2006-08-04       Impact factor: 5.464

Review 2.  T cell exhaustion during persistent viral infections.

Authors:  Shannon M Kahan; E John Wherry; Allan J Zajac
Journal:  Virology       Date:  2015-01-22       Impact factor: 3.616

3.  Timely triggering of homeostatic mechanisms involved in the regulation of T-cell levels in SIVsm-infected sooty mangabeys.

Authors:  Alagarraju Muthukumar; Dejiang Zhou; Mirko Paiardini; Ashley P Barry; Kelly S Cole; Harold M McClure; Silvija I Staprans; Guido Silvestri; Donald L Sodora
Journal:  Blood       Date:  2005-08-16       Impact factor: 22.113

4.  Qualitative immune modulation by interleukin-2 (IL-2) adjuvant therapy in immunological non responder HIV-infected patients.

Authors:  Francesca Sabbatini; Alessandra Bandera; Giulio Ferrario; Daria Trabattoni; Giulia Marchetti; Fabio Franzetti; Mario Clerici; Andrea Gori
Journal:  PLoS One       Date:  2010-11-29       Impact factor: 3.240

5.  CD8 apoptosis may be a predictor of T cell number normalization after immune reconstitution in HIV.

Authors:  Dorothy E Lewis; Kimber L Gross; Martine M Diez; Maria L Martinez; Helen N Lukefahr; Claudia A Kozinetz; Roberto C Arduino
Journal:  J Transl Med       Date:  2007-01-30       Impact factor: 5.531

Review 6.  Interleukin-2 as an adjunct to antiretroviral therapy for HIV-positive adults.

Authors:  Jennifer Onwumeh; Charles I Okwundu; Tamara Kredo
Journal:  Cochrane Database Syst Rev       Date:  2017-05-25

7.  Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR+ NK cell levels correlate with disease outcome.

Authors:  Nathalie Chaput; Caroline Flament; Clara Locher; Mélanie Desbois; Annie Rey; Sylvie Rusakiewicz; Vichnou Poirier-Colame; Patricia Pautier; Axel Le Cesne; Jean-Charles Soria; Angelo Paci; Michelle Rosenzwajg; David Klatzmann; Alexander Eggermont; Caroline Robert; Laurence Zitvogel
Journal:  Oncoimmunology       Date:  2013-02-01       Impact factor: 8.110

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.